Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03827447 · ClinicalTrials.gov registry record · Phase 1

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

A Phase 1 study of Clostridium Difficile Infection, sponsored by Medical College of Wisconsin.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
1
Study location

NCT03827447: Completed Phase 1 study of Clostridium Difficile Infection, sponsored by Medical College of Wisconsin.

NCT03827447 is a Phase 1 study of Clostridium Difficile Infection that has completed, run by Medical College of Wisconsin. The registered enrollment target is 7 participants, below the 12,065-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03827447, a Phase 1 study of Clostridium Difficile Infection, has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2. Determine the effect of oral vancomycin on structural and functional microbiome changes after end of treatment compared to a placebo group. 3. Characterize the impact of oral vancomycin against a placebo group on the daily frequency of loose stools by the end of treatment.

Primary Outcome

Compare the impact of vancomycin vs placebo on changes in C. difficile load from stool samples collected on Day 1 to end-of-treatment (Day 14) and to Day 28 using quantitative Polymerase Chain Reaction (qPCR).

Conditions Studied

Clostridium Difficile Infection

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Vancomycin Oral Capsule

Study Locations (1)

Wisconsin

  • Medical College of Wisconsin, Inc. - Milwaukee

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2019-07-17
Est. Completion 2021-06-30
Phase Phase 1
Medical College of Wisconsin

447 total trials

What the finished NCT03827447 record still lists

NCT03827447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 12,065-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT03827447 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT03827447 about?

NCT03827447 is a clinical study titled "Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile". This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2. Determine the effect of oral vancomycin on structural and functional microbiome changes after end of treatment compared to a placebo group. 3. Character...

What is the current status of trial NCT03827447?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-07-17. Estimated completion is 2021-06-30.

What conditions does trial NCT03827447 study?

This clinical trial studies the following conditions: Clostridium Difficile Infection.

What interventions are being tested in trial NCT03827447?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Vancomycin Oral Capsule (DRUG).

Who is sponsoring clinical trial NCT03827447?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03827447 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clostridium Difficile Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03827447's enrollment target sits among peer trials

7 13th of 13 higher than 1 of 13 other Clostridium Difficile Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clostridium Difficile Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03827447, the US trial registry maintained by the National Library of Medicine. NCT03827447 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.